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without dilatation of HA (using both Caselitz and Bus-
carini’s thresholds) had both color-spots and hypervascu-
larization, thus further supporting our statement that
intra-hepatic parameters have a better sensitivity and
accuracy than extrahepatic ultrasonography parameters
due to their ability to permit the diagnosis of even very
small AVMs in their early stage of development. Evi-
dently the presence of more severe vascular involvement
determines an angiodynamic remodelling and gross
abnormalities which can be detected on B-mode ultraso-
nographic study (mainly enlargement of HA in the
extrahepatic tract and ‘double channel aspect’ in the
portal spaces).
In conclusion, in this ﬁrst controlled, prospective
study, we have demonstrated that the diagnosis of
HAVMs in HHT can reliably be made by merely using
intra-hepatic parameters and does not require evidence
of extrahepatic abnormalities. The latter are useful to
grade the haemodynamic impact of HAVMs and the
possible eﬀect on liver angioarchitecture and clinical sig-
niﬁcance. We disagree with Dr. Buscarini’s ﬁnal com-
ment in which she states that ‘‘Doppler US diagnosis
of liver VMs in HHT requires a combination of extrahe-
patic and intra-hepatic ﬁndings, which can provide a
diagnostic accuracy ranging between 95% and 99% for
diﬀerent observers” [7] because in the absence of a stan-
dard reference technique, data on sensitivity and accu-
racy cannot be considered reliable.
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We have read with much interest the review by Este-
ban et al. on the changing epidemiology of hepatitis C
virus (HCV) infection in Europe [1]. Hepatitis C has be-
come a major public health problem worldwide with sig-
niﬁcant geographical and temporal heterogeneity. The
burden of HCV infection in Romania is an area of great
concern for at least three main reasons: (1) based on
scarce and outdated information, Romania is consid-
ered the European country with the highest prevalence
rate (double that of Spain or Greece, for example); (2)
Romania is one of the most important sources of mi-grant population towards Western Europe, in particular
to countries such as Spain and Italy, therefore altering
the decreasing trend of HCV prevalence in these coun-
tries; (3) last but not least, there is an urgent need for
a national strategy for the active detection and control
of the silent epidemic of HCV-infected population in
Romania. Although HCV infection is a major public
health problem in Romania, its prevalence in the general
population and its routes of transmission are largely un-
known. Before 1989, during the communist era, data on
the prevalence of viral hepatitis in Romania were scarce.
The reported prevalence of HCV infection in Romania
662 Letters to the Editor / Journal of Hepatology 49 (2008) 658–663used in the review by Esteban et al. is the result of a
seroprevalence survey conducted between April and July
1990 on a sample of 1355 persons recruited from the
population of Bucharest [2]. The population studied
consisted of a low-risk sample, comprising the following
groups: (1) children hospitalized for non-infectious dis-
eases, (2) pregnant women, and (3) healthy adults, and
a high-risk group comprising (1) children from ﬁve
orphanages in Bucharest and (2) healthcare workers
from four diﬀerent health facilities in Bucharest. The re-
ported prevalence of HCV infection in healthy adults
was 4.5% as compared with 16.9% in the high-risk group
of orphans [2]. From this point on, some other studies
on HCV prevalence in Romanian population were pub-
lished. In 1994, Molnar et al. reported a 4.9% HCV
prevalence in general population in three counties in
North-Western Transylvania [3]. In a multicentre study,
Grigorescu et al. analyzed the aetiological proﬁle of
chronic hepatitis and liver cirrhosis in Romania, show-
ing that HCV infection is responsible for 64% of chronic
hepatitis and 59% of liver cirrhosis [4]. In 2005, our
group found HCV infection to be responsible of 27.5%
of end-stage liver disease in patients awaiting liver trans-
plantation [5]. As Esteban et al. pointed out, the ﬁgures
described above have changed in Romania, such as in all
of Europe, in the last two decades due to the eradication
of transfusion-acquired infections, the great improve-
ment in healthcare facilities and the limited increase in
intravenous drug users (IDU) in our country. We take
this opportunity to present the preliminary data of a
nationwide cross-sectional survey scheduled to be car-
ried out between 2006 and 2008, aimed to determine
the prevalence and risk factors for HCV infection in
the general population in Romania through a multicen-
tre stratiﬁed random cluster sampling investigation. To
represent the geographical, economic, demographic, eth-
nic, and behavioural characteristics of the whole popula-
tion, Romania was divided into three initial main strata
representing the three geo-historical regions of Romania
(Table 1). Serum samples from 8039 healthy adults (re-
sponse rate 72%, aged 19–69 years) were tested for
anti-HCV antibodies with a third generation EIA and
conﬁrmed by PCR testing. Overall, 273 anti-HCV posi-
tive patients were detected (3.50%; CI 3.10–3.92%). The
prevalence of HCV infection for all of the 54 centres was
signiﬁcantly higher in rural areas (4.43%; CI 3.60–
5.23%) as compared to urban areas (2.76%; CI 2.26–
3.67%). A higher prevalence of HCV is associated with
older age groups (P = 0.002), lower education level
(P = 0.006) and lower income level (P = 0.0001). HCV
infection independently associated with the history of
transfusion, parenteral treatment, haemodialysis, and
IDU, suggesting that transfusions and contaminated
equipment used for medical procedures has played a
key role in HCV transmission among the Romanian
population. Finally, we fully agreed with Esteban et al.that large-scale epidemiological studies, including
molecular investigation, are required in order to esti-
mate the HCV burden and characteristics, especially in
new European countries, where scarce data are avail-
able, along with immediate measures to control (preven-
tion of nosocomial transmission, control of HCV
epidemic among IDU) and treat HCV infection.
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Table 1
Epidemiologic study and its results
Phase 1*
(December 2006–
March 2007)
Phase 2
(September–
December 2007)
Studied region of Romania Walachia Moldavia
Centres included** 20 34
Districts included 13 18
Subjects included 3092 4947
Anti-HCV positive
patients/ HCV RNA positive
93 (3.20%;
CI 2.59–3.91%)
180 (3.67%;
CI 3.16–4.23%)
*Phase = a pre-deﬁned (approximately 4 months) time interval in
which the sampling of study population in a geo-historical part of
Romania (Phase 1 – Walachia, Phase 2 – Moldavia) took place.
**Centre = the GP practice where the subjects (selected from the
healthy general population) were called on an outpatient visit to
answer a questionnaire and for blood sampling.
